This company has been marked as potentially delisted and may not be actively trading. resTORbio (TORC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock TORC vs. VIRI, WHWK, OSTX, ELYM, ATNM, NBRV, AADI, EGRX, PYRGF, and TAOXShould you be buying resTORbio stock or one of its competitors? The main competitors of resTORbio include Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), OS Therapies (OSTX), Eliem Therapeutics (ELYM), Actinium Pharmaceuticals (ATNM), Nabriva Therapeutics (NBRV), Aadi Bioscience (AADI), Eagle Pharmaceuticals (EGRX), PyroGenesis Canada (PYRGF), and Synaptogenix (TAOX). resTORbio vs. Its Competitors Virios Therapeutics Whitehawk Therapeutics OS Therapies Eliem Therapeutics Actinium Pharmaceuticals Nabriva Therapeutics Aadi Bioscience Eagle Pharmaceuticals PyroGenesis Canada Synaptogenix Virios Therapeutics (NASDAQ:VIRI) and resTORbio (NASDAQ:TORC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation. Do analysts rate VIRI or TORC? Virios Therapeutics currently has a consensus price target of $5.00, suggesting a potential upside of 0.81%. Given Virios Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Virios Therapeutics is more favorable than resTORbio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00resTORbio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better earnings & valuation, VIRI or TORC? Virios Therapeutics is trading at a lower price-to-earnings ratio than resTORbio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirios TherapeuticsN/AN/A-$5.30M-$0.27-18.37resTORbioN/AN/A-$82.74M-$2.41-0.30 Does the media prefer VIRI or TORC? In the previous week, Virios Therapeutics' average media sentiment score of 0.00 equaled resTORbio'saverage media sentiment score. Company Overall Sentiment Virios Therapeutics Neutral resTORbio Neutral Is VIRI or TORC more profitable? resTORbio's return on equity of -78.12% beat Virios Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Virios TherapeuticsN/A -130.33% -115.00% resTORbio N/A -78.12%-71.63% Which has more volatility & risk, VIRI or TORC? Virios Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Comparatively, resTORbio has a beta of 2.43, suggesting that its stock price is 143% more volatile than the S&P 500. Do institutionals & insiders hold more shares of VIRI or TORC? 9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 46.2% of resTORbio shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by company insiders. Comparatively, 11.8% of resTORbio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryVirios Therapeutics and resTORbio tied by winning 5 of the 10 factors compared between the two stocks. Get resTORbio News Delivered to You Automatically Sign up to receive the latest news and ratings for TORC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TORC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TORC vs. The Competition Export to ExcelMetricresTORbioPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.25M$827.86M$5.66B$9.84BDividend YieldN/A4.84%3.93%4.04%P/E Ratio-0.401.1283.2726.61Price / SalesN/A120.95451.26176.34Price / CashN/A19.5637.7059.65Price / Book0.326.6110.556.59Net Income-$82.74M-$5.06M$3.27B$266.12M resTORbio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TORCresTORbioN/A$0.72-5.1%N/A-48.0%$26.25MN/A-0.40N/AVIRIVirios TherapeuticsN/A$5.06+2.3%$5.00-1.2%+2,563.9%$97.45MN/A-18.745News CoverageGap UpWHWKWhitehawk TherapeuticsN/A$1.81+6.5%N/AN/A$80.12M$21.60M-30.1740Positive NewsOSTXOS Therapies2.1673 of 5 stars$2.33+6.4%$18.00+672.5%-34.0%$74.31MN/A-2.95N/AAnalyst ForecastELYMEliem TherapeuticsN/A$2.48+4.2%N/A-68.8%$73.79MN/A-4.689Positive NewsGap UpHigh Trading VolumeATNMActinium Pharmaceuticals2.3779 of 5 stars$1.78-0.6%$4.50+152.8%-6.8%$55.53MN/A-1.2830NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070AADIAadi BioscienceN/A$1.70-2.3%N/A+1.1%$41.99M$25.07M-0.7540EGRXEagle Pharmaceuticals1.654 of 5 stars$3.19flatN/A-41.0%$41.43M$257.55M0.00100News CoverageGap DownPYRGFPyroGenesis CanadaN/A$0.22+2.4%N/A-65.2%$41.33M$9.14M-3.6790TAOXSynaptogenixN/A$6.96-0.7%N/AN/A$24.45M$3.96K-0.354 Related Companies and Tools Related Companies Virios Therapeutics Alternatives Whitehawk Therapeutics Alternatives OS Therapies Alternatives Eliem Therapeutics Alternatives Actinium Pharmaceuticals Alternatives Nabriva Therapeutics Alternatives Aadi Bioscience Alternatives Eagle Pharmaceuticals Alternatives PyroGenesis Canada Alternatives Synaptogenix Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TORC) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding resTORbio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share resTORbio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
